TEVA, US8816242098

Teva Pharmaceutical Industries stock tracks DEGEVMA FDA approval

Published on 10/05/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva Pharmaceutical Industries stock was at USD 39.92 on October 5, while FDA approval added a second denosumab biosimilar to its 2026 portfolio. Q2 revenue fell 1 percent year over year.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Limited stock (ISIN US8816242098) was trading at USD 39.92 on the NYSE on October 5, 2026, up USD 0.39 or 0.99 percent from the prior close. The latest catalyst is DEGEVMA, a denosumab biosimilar approved by the U.S. Food and Drug Administration, as PharmaTimes reported on October 5, 2026.

DEGEVMA expands biosimilar reach

Teva's official release dated September 28, 2026, says DEGEVMA is approved across the indications of Xgeva, including bone complications linked to advanced cancer, giant cell tumor of bone and hypercalcemia of malignancy, according to Teva.

DEGEVMA is Teva's second FDA-approved biosimilar in 2026. Together with PONLIMSI, approved in March 2026, the products cover the denosumab indications associated with Xgeva and Prolia, giving Teva a broader U.S. platform in oncology-related bone disease and osteoporosis care.

Q2 revenue sets the baseline

Teva reported USD 4.14 billion in second-quarter 2026 revenue, down 1 percent from the same quarter a year earlier, while U.S. generics remained a pressure point. The period also included a net loss of USD 576 million and diluted GAAP EPS of negative USD 0.49, according to the company's Q2 filing summary published by StockTitan.

The contrast is important for the biosimilar story: revenue contracted year over year in Q2, while the latest product approval adds another commercial asset to the growth strategy. Teva also expects to launch DEGEVMA and PONLIMSI in the United States in the coming months.

Analysts see a higher target

TD Cowen initiated coverage on October 1, 2026, with a Buy rating and a USD 55 price target, according to MarketBeat. The target lies 37.9 percent above the USD 39.92 NYSE price.

MarketBeat's analyst tally showed 12 Buy ratings and one Hold rating, producing a Moderate Buy consensus and an average price target of USD 44.67. That average target lies 11.9 percent above the NYSE price, so the consensus is less aggressive than TD Cowen's individual view.

Stock stays near yearly high

At USD 39.92 on October 5, 2026, Teva stock was 2.13 percent below its 52-week high of USD 40.79 and 112.1 percent above its 52-week low of USD 18.83. Trading volume stood at 1,085,368 shares, and market capitalization was USD 46.5 billion.